Table 1.
Baseline characteristics of SHARP patients included in the cost analysis
| By baseline CKD stage 1 | Overall | ||||
|---|---|---|---|---|---|
| CKD 1-3B (eGFR: ≥30) 2 | CKD 4 (eGFR: ≥15, <30) | CKD 5 (eGFR: <15 not on dialysis) | On dialysis | ||
| Number of patients | 1,494 | 2,228 | 1,017 | 2,498 | 7,246 |
| Men | 1,078 (72%) | 1,368 (61%) | 599 (59%) | 1,600 (64%) | 4,652 (64%) |
| Age (years) | 62 (11) | 65 (12) | 63 (12) | 61 (12) | 63 (12) |
| Prior vascular disease | 189 (13%) | 350 (16%) | 147 (14%) | 428 (17%) | 1,116 (15%) |
| Prior diabetes mellitus | 268 (18%) | 454 (20%) | 169 (17%) | 546 (22%) | 1,439 (20%) |
| Current smoker | 205 (14%) | 276 (12%) | 133 (13%) | 432 (17%) | 1,048 (14%) |
| Body-mass index (kg/m2) | 28.4 (5.3) | 28.2 (5.8) | 27.5 (5.5) | 27.0 (5.9) | 27.8 (5.7) |
| Diastolic blood pressure (mm Hg) | 80 (13) | 79 (13) | 80 (12) | 77 (13) | 79 (13) |
| Systolic blood pressure (mm Hg) | 138 (20) | 138 (20) | 141 (20) | 137 (24) | 138 (21) |
| Total cholesterol (mmol/L) | 5.1 (1.1) | 5.1 (1.1) | 4.9 (1.2) | 4.6 (1.2) | 4.9 (1.2) |
| LDL cholesterol (mmol/L) | 3.0 (0.8) | 2.9 (0.8) | 2.8 (0.9) | 2.6 (0.9) | 2.8 (0.9) |
| HDL cholesterol (mmol/L) | 1.2 (0.3) | 1.2 (0.3) | 1.1 (0.3) | 1.1 (0.4) | 1.1 (0.3) |
| Triglycerides (mmol/L) | 2.3 (1.6) | 2.3 (1.4) | 2.2 (1.4) | 2.3 (1.9) | 2.3 (1.6) |
| Renal status | |||||
| On dialysis | - | - | - | 2,498 (100%) | 2,498 (34%) |
| Hemodialysis | - | - | - | 2,076 (83%) | 2,076 (29%) |
| Peritoneal dialysis | - | - | - | 422 (17%) | 422 (6%) |
| Not on dialysis | 1,494 (100%) | 2,228 (100%) | 1,017 (100%) | - | 4,739 (65%) |
| Estimated glomerular filtration rate (mL/min/1.732) | 37.6 (6.5) | 22.5 (4.3) | 10.8 (2.7) | - | 24.8 (10.9) |
| Urinary albumin:creatinine ratio (mg/g)3 | |||||
| Median (IQR) | 75 (16–328) | 155 (36–592) | 397 (124–1,204) | - | 156 (35–626) |
| <30 | 459 (36%) | 426 (22%) | 62 (7%) | - | 947 (23%) |
| ≥30, ≤ 300 | 496 (38%) | 820 (42%) | 332 (37%) | - | 1,648 (40%) |
| >300 | 336 (26%) | 722 (37%) | 511 (56%) | - | 1,569 (38%) |
| Not available | 203 | 260 | 112 | - | 584 |
| Region of recruitment | |||||
| Europe | 1,022 (68%) | 1,546 (69%) | 730 (72%) | 1,779 (71%) | 5,083 (70%) |
| Australasia | 260 (17%) | 446 (20%) | 187 (18%) | 408 (16%) | 1,302 (18%) |
| North America | 212 (14%) | 236 (11%) | 100 (10%) | 311 (12%) | 861 (12%) |
Data are n (%), mean (SD) or median (IQR); CKD = chronic kidney disease.
19 patients who received a transplant prior to randomization were excluded from the tabulation by baseline CKD stage.
2Predominantly CKD stage 3B (eGFR ≥30 to <45 ml/min/1.73m2).
3Percentages exclude patients for whom data were not available.